Survival and gastrostomy prevalence in patients with oropharyngeal cancer treated with transoral robotic surgery vs chemoradiotherapy

Arun Sharma, Sapna Patel, Fred M. Baik, Grant Mathison, Brendan H G Pierce, Samir S. Khariwala, Bevan Yueh, Stephen M. Schwartz, Eduardo Méndez

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Importance Treatment of oropharyngeal squamous cell carcinoma (OPSCC) presents unique challenges and can be associated with significant morbidity. Transoral robotic surgery (TORS) has emerged as a treatment modality for OPSCC, but data comparing outcomes between patients treated with TORS-based therapy and nonsurgical therapy are limited. Objective To compare survival and gastrostomy prevalence between patients with OPSCC treated with TORS-based therapy and those treated with nonsurgical therapy. Design, Setting, and Participants This retrospective matched-cohort study identified patients with OPSCC treated at the University ofWashington and University of Minnesota tertiary care medical centers from January 1, 2005, to December 31, 2013. Each patient treated with TORS-based therapy was matched by stage with as many as 3 patients treated with nonsurgical therapy. Final follow-up was completed on April 1, 2015. Main Outcomes and Measures Disease-free survival, overall survival, and gastrostomy tube prevalence. Results One hundred twenty-seven patients met the study criteria (113 men [89.0%]; 14 women [11.0%]; median [interquartile range] age, 57 [52-63] years); 39 patients who underwent TORS were matched to 88 patients who underwent nonsurgical therapy. Compared with the nonsurgical group, more patients had p16-positive tumors in the TORS group (30 of 31 [96.8%] vs 30 of 37 [81.1%] among patients with known p16 status). No statistically significant difference in survival between treatment groups was found in multivariable analysis (disease-free survival hazard ratio, 0.22; 95%CI, 0.04-1.36; P = .10). Patients who received TORS-based therapy had lower gastrostomy tube prevalence after treatment (13 of 39 [33.3%] vs 74 of 88 [84.1%]) for a univariable relative risk of 0.43 (95% CI, 0.27-0.67; P < .001) and a multivariable relative risk of 0.43 (95%CI, 0.27-0.68; P < .001). Gastrostomy prevalence decreased by time after treatment for both groups (TORS group: 3 of 34 [9%] at 3 months to 1 of 33 [3%] at 12 months; nonsurgical group: 37 of 82 [45%] at 3 months to 7 of 66 [11%] at 12 months). Conclusions and Relevance Patients undergoing TORS for OPSCC have statistically indistinguishable survival but lower gastrostomy prevalence compared with patients undergoing nonsurgical therapy for stage-matched OPSCC. TORS offers promise for improved swallowing function in patients with OPSCC.

Original languageEnglish (US)
Pages (from-to)691-697
Number of pages7
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume142
Issue number7
DOIs
StatePublished - Jul 2016

Bibliographical note

Funding Information:
This study was supported by grant 5T32DC000018-30 from the National Institutes of Health and grant RSG TBG-123653 from the American Cancer Society.

Fingerprint Dive into the research topics of 'Survival and gastrostomy prevalence in patients with oropharyngeal cancer treated with transoral robotic surgery vs chemoradiotherapy'. Together they form a unique fingerprint.

Cite this